Literature DB >> 15139473

Tuberculosis in California dialysis patients.

A T Ahmed1, A J Karter.   

Abstract

SETTING: Kaiser Permanente Northern California dialysis registry.
OBJECTIVE: To examine the incidence of tuberculosis disease (TB) in a large, insured population of dialysis patients and to describe the disease characteristics and outcomes of these cases.
DESIGN: Cohort study of all Kaiser patients who initiated dialysis between 1 January 1995 and 31 December 1999. TB incidence in our cohort between 1 January 1995 and 31 December 2000 was determined through electronic databases of out-patient diagnoses, laboratory results, and pharmacy records. The incidence of TB in the general population was determined from mandatory reporting of TB cases compiled by the California Department of Health Services.
RESULTS: During the 6-year period of observation, 13 cases of TB occurred among 2806 dialysis initiators. The incidence of TB in the dialysis cohort was 134 per 100,000 person-years, compared to an incidence of 11.9/100,000 in the California population, yielding a relative risk of 11.3. Extra-pulmonary disease occurred in eight of 11 patients for whom site of disease was recorded. Five of 13 patients died within 3 months of TB diagnosis.
CONCLUSIONS: The dialysis population is at high risk of TB. Physicians caring for dialysis patients must remain vigilant for signs of TB in this vulnerable population.

Entities:  

Mesh:

Year:  2004        PMID: 15139473

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  5 in total

1.  Interferon-gamma release assays are a better tuberculosis screening test for hemodialysis patients: A study and review of the literature.

Authors:  J Grant; J Jastrzebski; J Johnston; A Stefanovic; J Jastrabesky; K Elwood; D Roscoe; R Balshaw; E Bryce
Journal:  Can J Infect Dis Med Microbiol       Date:  2012       Impact factor: 2.471

2.  Tolerability and Healthcare Utilization in Maintenance Hemodialysis Patients Undergoing Treatment for Tuberculosis-Related Conditions.

Authors:  Abdurrahman M Hamadah; Lynn M Beaulieu; John W Wilson; Timothy R Aksamit; James R Gregoire; Amy W Williams; John J Dillon; Robert C Albright; Macaulay Onuigbo; Venkateshwaran K Iyer; LaTonya J Hickson
Journal:  Nephron       Date:  2016-02-10       Impact factor: 2.847

3.  Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis.

Authors:  Payam Nahid; Susan E Dorman; Narges Alipanah; Pennan M Barry; Jan L Brozek; Adithya Cattamanchi; Lelia H Chaisson; Richard E Chaisson; Charles L Daley; Malgosia Grzemska; Julie M Higashi; Christine S Ho; Philip C Hopewell; Salmaan A Keshavjee; Christian Lienhardt; Richard Menzies; Cynthia Merrifield; Masahiro Narita; Rick O'Brien; Charles A Peloquin; Ann Raftery; Jussi Saukkonen; H Simon Schaaf; Giovanni Sotgiu; Jeffrey R Starke; Giovanni Battista Migliori; Andrew Vernon
Journal:  Clin Infect Dis       Date:  2016-08-10       Impact factor: 9.079

4.  Risk of tuberculosis in dialysis patients: a nationwide cohort study.

Authors:  Claudia C Dobler; Stephen P McDonald; Guy B Marks
Journal:  PLoS One       Date:  2011-12-27       Impact factor: 3.240

Review 5.  Rediscovering Beta-2 Microglobulin As a Biomarker across the Spectrum of Kidney Diseases.

Authors:  Christos P Argyropoulos; Shan Shan Chen; Yue-Harn Ng; Maria-Eleni Roumelioti; Kamran Shaffi; Pooja P Singh; Antonios H Tzamaloukas
Journal:  Front Med (Lausanne)       Date:  2017-06-15
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.